|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-2-18
|
|
pubmed:abstractText |
In the PURSUIT trial, eptifibatide significantly reduced the 30-day incidence of death and myocardial infarction relative to placebo in 9461 patients with an acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
366-71
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10653826-Angina, Unstable,
pubmed-meshheading:10653826-Cost-Benefit Analysis,
pubmed-meshheading:10653826-Female,
pubmed-meshheading:10653826-Follow-Up Studies,
pubmed-meshheading:10653826-Humans,
pubmed-meshheading:10653826-Length of Stay,
pubmed-meshheading:10653826-Male,
pubmed-meshheading:10653826-Middle Aged,
pubmed-meshheading:10653826-Myocardial Infarction,
pubmed-meshheading:10653826-Peptides,
pubmed-meshheading:10653826-Platelet Aggregation Inhibitors,
pubmed-meshheading:10653826-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:10653826-Prospective Studies,
pubmed-meshheading:10653826-Risk Factors,
pubmed-meshheading:10653826-United States
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
|
|
pubmed:affiliation |
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA. daniel.mark@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
